Tinya J Abrams

Summary

Affiliation: Preclinical Research and Exploratory Development
Country: USA

Publications

  1. ncbi SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
    Tinya J Abrams
    Preclinical Research and Exploratory Development, SUGEN, Inc, South San Francisco, California 94080, USA
    Mol Cancer Ther 2:471-8. 2003
  2. ncbi Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer
    Tinya J Abrams
    Preclinical Research and Experimental Development, SUGEN, Inc, South San Francisco, CA 94080, USA
    Mol Cancer Ther 2:1011-21. 2003
  3. ncbi SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
    Lesley J Murray
    SUGEN, Inc South San Francisco, California, USA
    Clin Exp Metastasis 20:757-66. 2003
  4. ncbi In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
    Dirk B Mendel
    Preclinical Research and Exploratory Development, SUGEN, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 9:327-37. 2003
  5. ncbi SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    Anne Marie O'Farrell
    Preclinical Research and Exploratory Development, SUGEN, South San Francisco, CA 94080, USA
    Blood 101:3597-605. 2003
  6. ncbi A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657
    Jastinder Sohal
    Comprehensive Cancer Center and the Department of Laboratory Medicine, University of California, San Francisco, 94143, USA
    Blood 101:3188-97. 2003
  7. ncbi CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice
    Xiaohua Xin
    Translational Sciences, Chiron Corporation, Emeryville, California, USA
    Clin Cancer Res 12:4908-15. 2006

Collaborators

Detail Information

Publications7

  1. ncbi SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
    Tinya J Abrams
    Preclinical Research and Exploratory Development, SUGEN, Inc, South San Francisco, California 94080, USA
    Mol Cancer Ther 2:471-8. 2003
    ....
  2. ncbi Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer
    Tinya J Abrams
    Preclinical Research and Experimental Development, SUGEN, Inc, South San Francisco, CA 94080, USA
    Mol Cancer Ther 2:1011-21. 2003
    ..05). These results demonstrate that SU11248 is effective in preclinical breast cancer models and suggest that it may be useful in the treatment of breast cancer in the clinic...
  3. ncbi SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
    Lesley J Murray
    SUGEN, Inc South San Francisco, California, USA
    Clin Exp Metastasis 20:757-66. 2003
    ..001). Collectively, these data suggest that SU11248 may be an effective and tolerated therapy to inhibit growth of breast cancer bone metastases, with the additional advantage of inhibiting tumor-associated osteolysis...
  4. ncbi In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
    Dirk B Mendel
    Preclinical Research and Exploratory Development, SUGEN, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 9:327-37. 2003
    ..The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials...
  5. ncbi SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    Anne Marie O'Farrell
    Preclinical Research and Exploratory Development, SUGEN, South San Francisco, CA 94080, USA
    Blood 101:3597-605. 2003
    ..These results suggest that further exploration of SU11248 activity in AML patients is warranted...
  6. ncbi A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657
    Jastinder Sohal
    Comprehensive Cancer Center and the Department of Laboratory Medicine, University of California, San Francisco, 94143, USA
    Blood 101:3188-97. 2003
    ..Our findings also indicate that APL patients with FLT3 mutations may benefit from combination therapy with all-trans retinoic acid plus an FLT3 inhibitor...
  7. ncbi CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice
    Xiaohua Xin
    Translational Sciences, Chiron Corporation, Emeryville, California, USA
    Clin Cancer Res 12:4908-15. 2006
    ..CONCLUSIONS: Our data provide a relevant preclinical basis for clinical trials of CHIR-258 in FGFR3-positive MM patients...